SYSTEMATIC REVIEW article
Front. Pharmacol.
Sec. Ethnopharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1538692
This article is part of the Research TopicTraditional Medicines in the Treatment of Infectious Diseases – Challenges and advancesView all 6 articles
Efficacy and Safety of Baihe Gujin Decoction as an Adjunct to Chemotherapy in Pulmonary Tuberculosis: A Systematic Review and Meta-Analysis
Provisionally accepted- 1Graduate School, Hebei North University, Zhangjiakou, Hebei Province, China
- 2Senior Department of Tuberculosis, The 8th Medical Center of PLA General Hospital, Beijing, China
- 3Beijing Geriatric Hospital, Beijing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Pulmonary tuberculosis (PTB), an ancient affliction, continues to present significant challenges in modern medicine. Baihe Gujin Decoction, a traditional Chinese botanical drug remedy, has been widely utilized in clinical practice for tuberculosis treatment, yet its efficacy has been inconsistent. This meta-analysis aims to ascertain its effectiveness and contribute to evidence-based medicine. Methods: A comprehensive search was conducted across multiple databases, including PubMed, Embase, The Cochrane Library, China Science and Technology Journal Database, Wanfang Database, China Biomedical Literature Database, and China National Knowledge Infrastructure, to identify relevant randomized controlled trials from January 2010 to February 2024. The risk of bias in the included studies was assessed using the Cochrane Collaboration's tool, and meta-analyses were performed using Review Manager and Stata to evaluate the comparative outcomes. Results: This meta-analysis encompassed 32 studies. The control group exhibited a notably higher clinical overall efficacy rate [OR=5.50, 95%CI (4.18, 7.24), P<0.05], lesion absorption rate [OR=5.83, 95%CI (4.08, 8.33), P<0.05], cavity change rate [OR=2.35, 95%CI (1.50, 3.69), P<0.05], and sputum negative conversion rate [OR=2.85, 95%CI (2.12, 3.83), P<0.05]. In contrast, the treatment group demonstrated an increase in CD4+ T lymphocyte subset levels post-treatment, with a weighted mean difference of [OR=4.87, (95%CI (1.91, 7.83), P<0.05]. Furthermore, safety indices, including the incidence of total adverse reactions, liver function abnormalities, and gastrointestinal reactions, were significantly lower in the treatment group. Conclusions: The combination of Baihe Gujin Decoction with biomedicine is more efficacious than biomedicine alone for treating PTB. This superiority is evident in improved clinical efficacy rates, lesion absorption, cavity changes, sputum negative conversion rates, and immune indices, alongside a reduced incidence of adverse reactions.
Keywords: pulmonary tuberculosis, Baihe Gujin decoction, Anti-tuberculosis drugs, Meta-analysis, randomized controlled trial
Received: 03 Dec 2024; Accepted: 23 Apr 2025.
Copyright: © 2025 Zhao, Han, Liu, Niu, Wang, Li, Liang and Gong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Jianqin Liang, Senior Department of Tuberculosis, The 8th Medical Center of PLA General Hospital, Beijing, China
Wenping Gong, Senior Department of Tuberculosis, The 8th Medical Center of PLA General Hospital, Beijing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.